<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00053482</url>
  </required_header>
  <id_info>
    <org_study_id>H-400-003</org_study_id>
    <nct_id>NCT00053482</nct_id>
  </id_info>
  <brief_title>Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults</brief_title>
  <official_title>The Effect of Dose on Safety, Tolerability, and Immunogenicity of ACAM2000 Smallpox Vaccine in Adults With Previous Smallpox Vaccination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emergent BioSolutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emergent BioSolutions</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the minimum dose of ACAM2000 needed to produce a
      cutaneous reaction in at least 90% of a population of healthy adults at least 28 years of age
      and previously vaccinated against smallpox.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specifically, the objectives of this study are to:

        1. Compare the safety and tolerability of four dose levels of ACAM2000 and a standard dose
           of Dryvax® in healthy adults at least 28 years of age and previously vaccinated to
           smallpox. Safety and tolerability will be determined by examination of the local
           cutaneous reaction, adverse events, physical examinations, vital signs, structured
           interviews, and laboratory analysis.

        2. Determine the immunogenicity of four dose levels of ACAM2000 and a standard dose of
           Dryvax® in healthy adults at least 28 years of age by comparing:

             1. the proportion of subjects at each dose level who develop a major cutaneous
                reaction

             2. the proportion of subjects in each treatment group who develop neutralizing
                antibodies, including the fold-increase in antibody titer between Baseline and Day
                30 sera; and the geometric mean vaccinia neutralizing antibody titer on Day 30.

        3. Determine the minimum dose of ACAM2000 that is calculated to produce a major cutaneous
           reaction in at least 90% of a population of healthy adults at least 28 years of age,
           with a history of smallpox vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">October 2003</completion_date>
  <primary_completion_date type="Actual">April 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Neutralizing Antibody Response Titers Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</measure>
    <time_frame>Day 30 post-vaccination</time_frame>
    <description>The neutralizing antibody response titers were determined by the Plaque-Reduction Neutralization Test (PRNT50)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With ≥ 4-fold Increase in Plaque-Reduction Neutralization Test (PRNT50) Titers Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine.</measure>
    <time_frame>Day 30 post-vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Adverse Events of Severe Intensity Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</measure>
    <time_frame>Days 0 to 30 post-vaccination</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Number of Participants With Treatment-Emergent Rash Events Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</measure>
    <time_frame>Days 0 to 30 post-vaccination</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Selected Hematology Parameters (Hematocrit, Lymphocyte, and Eosinophil) at Baseline and Day 15 Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</measure>
    <time_frame>Days 0 (Baseline) and 15 post-vaccination</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Selected Hematology Parameters (Red Bood Cell and Platelets) at Baseline and Day 15 Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</measure>
    <time_frame>Days 0 (Baseline) and 15 post-vaccination</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Chemistry Parameters (Creatinine and Glucose) at Baseline and Day 15 Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</measure>
    <time_frame>Days 0 (Baseline) and 15 post-vaccination</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Chemistry Parameters (Aspartate Transaminase and Alanine Transaminase) at Baseline and Day 15 Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</measure>
    <time_frame>Days 0 (Baseline) and 15 post-vaccination</time_frame>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">357</enrollment>
  <condition>Smallpox</condition>
  <arm_group>
    <arm_group_label>Group 1: ACAM2000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive dose 1 of the ACAM2000 smallpox vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: ACAM2000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive dose 2 of the ACAM2000 smallpox vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: ACAM2000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive dose 3 of the ACAM2000 smallpox vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: ACAM2000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive dose 4 of the ACAM2000 smallpox vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: Dryvax®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive dose 1 of Dryvax® smallpox vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACAM2000 Smallpox Vaccine</intervention_name>
    <description>Group 1 dose: 1.0x10-8th PFU/ml, Group 2 dose: 2.0x10-7th PFU/ml, Group 3 dose: 1.0x10-7th PFU/ml, Group 4 dose: 5.0x10-6th PFUL/ml</description>
    <arm_group_label>Group 1: ACAM2000</arm_group_label>
    <arm_group_label>Group 2: ACAM2000</arm_group_label>
    <arm_group_label>Group 3: ACAM2000</arm_group_label>
    <arm_group_label>Group 4: ACAM2000</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®</intervention_name>
    <description>Group 5 dose: 1.0x10-8th PFU/ml</description>
    <arm_group_label>Group 5: Dryvax®</arm_group_label>
    <other_name>Dryvax®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  have a history of previous smallpox vaccination greater than 10 years previous to the
             date of screening and presence of a vaccination scar.

          -  females must not be pregnant, lactating and must agree to use an effective form of
             birth control for the 30 days following vaccination or unable to bear children.

          -  agree to be available for the entire study and agree to comply with all requirements.

        exclusion criteria:

          -  children 1 year of age or younger in the household or be in close contact

          -  smallpox vaccination within ten years

          -  known or suspected Human immunodeficient virus (HIV) infection, primary
             immunodeficiency disorder, leukemia, lymphoma, or current radiation treatment or use
             of immunosuppressive or anti-neoplastic drugs or have a household member or intimate
             contact with the conditions listed above.

          -  renal disease

          -  current or past history of eczema or a household member or direct contact who has
             eczema.

          -  known allergy or past allergic reactions to latex gloves or to antibiotics which
             include neomycin, streptomycin, chlortetracycline, and polymyxin B

          -  known allergy or past allergic reaction to blood products.

          -  known allergy to cidofovir or sulfa-containing drugs.

          -  history of allergic phenomena following smallpox vaccination in the past, including
             urticaria, erythema multiforme, or Stevens-Johnson syndrome.

          -  transfusion of blood or treatment with any blood product.

          -  current or history of drug or alcohol abuse

          -  innoculation with any other live vaccine or participating in another drug or vaccine
             trial within 30 days of enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>28 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Emergent BioSolutions</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA International</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bio-Kinetic Clinical Applications</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital of Rhode Island Division of Infectious Diseases</name>
      <address>
        <city>Pawtucket</city>
        <state>Rhode Island</state>
        <zip>02860</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2003</study_first_submitted>
  <study_first_submitted_qc>January 30, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2003</study_first_posted>
  <results_first_submitted>January 3, 2011</results_first_submitted>
  <results_first_submitted_qc>January 14, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2011</results_first_posted>
  <last_update_submitted>January 26, 2018</last_update_submitted>
  <last_update_submitted_qc>January 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smallpox vaccines</keyword>
  <keyword>Dryvax®</keyword>
  <keyword>Orthopoxvirus</keyword>
  <keyword>Vaccinia virus</keyword>
  <keyword>ACAM2000</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Smallpox</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 07 January 2003 to 31 March 2003 in 3 medical centers in the US.</recruitment_details>
      <pre_assignment_details>A total of 357 participants who met the inclusion and exclusion criteria were enrolled and vaccinated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ACAM2000 Dose 1</title>
          <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0</description>
        </group>
        <group group_id="P2">
          <title>ACAM2000 Dose 2</title>
          <description>Participants received a single dose of ACAM2000 smallpox vaccine, 2.0x10-7th plaque-forming units/mL on Day 0</description>
        </group>
        <group group_id="P3">
          <title>ACAM2000 Dose 3</title>
          <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10-7th plaque-forming units/mL on Day 0</description>
        </group>
        <group group_id="P4">
          <title>ACAM2000 Dose 4</title>
          <description>Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10-6th plaque-forming units/mL on Day 0</description>
        </group>
        <group group_id="P5">
          <title>Dryvax® Vaccine</title>
          <description>Participants received a single dose of Dryvax® smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="102"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="102"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ACAM2000 Dose 1</title>
          <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0</description>
        </group>
        <group group_id="B2">
          <title>ACAM2000 Dose 2</title>
          <description>Participants received a single dose of ACAM2000 smallpox vaccine, 2.0x10-7th plaque-forming units/mL on Day 0</description>
        </group>
        <group group_id="B3">
          <title>ACAM2000 Dose 3</title>
          <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10-7th plaque-forming units/mL on Day 0</description>
        </group>
        <group group_id="B4">
          <title>ACAM2000 Dose 4</title>
          <description>Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10-6th plaque-forming units/mL on Day 0</description>
        </group>
        <group group_id="B5">
          <title>Dryvax® Vaccine</title>
          <description>Participants received a single dose of Dryvax® smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="102"/>
            <count group_id="B3" value="102"/>
            <count group_id="B4" value="50"/>
            <count group_id="B5" value="52"/>
            <count group_id="B6" value="357"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="102"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="52"/>
                    <measurement group_id="B6" value="357"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" spread="9.7"/>
                    <measurement group_id="B2" value="48" spread="10.1"/>
                    <measurement group_id="B3" value="50" spread="11.7"/>
                    <measurement group_id="B4" value="47" spread="9.1"/>
                    <measurement group_id="B5" value="48" spread="9.2"/>
                    <measurement group_id="B6" value="48" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="175"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="102"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="52"/>
                    <measurement group_id="B6" value="357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Neutralizing Antibody Response Titers Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</title>
        <description>The neutralizing antibody response titers were determined by the Plaque-Reduction Neutralization Test (PRNT50)</description>
        <time_frame>Day 30 post-vaccination</time_frame>
        <population>The neutralizing antibody response titers were assessed in the antibody evaluable, per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>ACAM2000 Dose 1</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O2">
            <title>ACAM2000 Dose 2</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 2.0x10-7th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O3">
            <title>ACAM2000 Dose 3</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10-7th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O4">
            <title>ACAM2000 Dose 4</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10-6th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Dryvax® Vaccine</title>
            <description>Participants received a single dose of Dryvax® smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>The Neutralizing Antibody Response Titers Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</title>
          <description>The neutralizing antibody response titers were determined by the Plaque-Reduction Neutralization Test (PRNT50)</description>
          <population>The neutralizing antibody response titers were assessed in the antibody evaluable, per-protocol population.</population>
          <units>PRNT50 Titers</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" spread="119.4"/>
                    <measurement group_id="O2" value="112" spread="280.5"/>
                    <measurement group_id="O3" value="76" spread="108.7"/>
                    <measurement group_id="O4" value="91" spread="145.4"/>
                    <measurement group_id="O5" value="186" spread="709.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244" spread="485.4"/>
                    <measurement group_id="O2" value="259" spread="449.1"/>
                    <measurement group_id="O3" value="802" spread="4111.6"/>
                    <measurement group_id="O4" value="546" spread="829.9"/>
                    <measurement group_id="O5" value="1287" spread="2198.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With ≥ 4-fold Increase in Plaque-Reduction Neutralization Test (PRNT50) Titers Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine.</title>
        <time_frame>Day 30 post-vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ACAM2000 Dose 1</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O2">
            <title>ACAM2000 Dose 2</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 2.0x10-7th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O3">
            <title>ACAM2000 Dose 3</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10-7th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O4">
            <title>ACAM2000 Dose 4</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10-6th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Dryvax® Vaccine</title>
            <description>Participants received a single dose of Dryvax® smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With ≥ 4-fold Increase in Plaque-Reduction Neutralization Test (PRNT50) Titers Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine.</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Adverse Events of Severe Intensity Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</title>
        <time_frame>Days 0 to 30 post-vaccination</time_frame>
        <population>Post-vaccination adverse events were assessed in the safety, intent-to-treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>ACAM2000 Dose 1</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O2">
            <title>ACAM2000 Dose 2</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 2.0x10-7th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O3">
            <title>ACAM2000 Dose 3</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10-7th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O4">
            <title>ACAM2000 Dose 4</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10-6th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Dryvax® Vaccine</title>
            <description>Participants received a single dose of Dryvax® smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Adverse Events of Severe Intensity Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</title>
          <population>Post-vaccination adverse events were assessed in the safety, intent-to-treat population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lymph Node Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphadenopathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Toothache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Pruritus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Human Immunodeficiency Virus (HIV) Test Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Back Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling Not Otherwise Specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Migraine Not Otherwise Specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pregnancy Not Otherwise Specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calculus Renal Not Otherwise Specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Treatment-Emergent Rash Events Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</title>
        <time_frame>Days 0 to 30 post-vaccination</time_frame>
        <population>Treatment-emergent rash events were assessed in the safety intent-to-treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>ACAM2000 Dose 1</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O2">
            <title>ACAM2000 Dose 2</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 2.0x10-7th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O3">
            <title>ACAM2000 Dose 3</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10-7th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O4">
            <title>ACAM2000 Dose 4</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10-6th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Dryvax® Vaccine</title>
            <description>Participants received a single dose of Dryvax® smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Rash Events Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</title>
          <population>Treatment-emergent rash events were assessed in the safety intent-to-treat population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rash Not Otherwise Specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash Macular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash Papular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Application Site Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Selected Hematology Parameters (Hematocrit, Lymphocyte, and Eosinophil) at Baseline and Day 15 Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</title>
        <time_frame>Days 0 (Baseline) and 15 post-vaccination</time_frame>
        <population>The hematology parameters were assessed in the intent-to-treat safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>ACAM2000 Dose 1</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O2">
            <title>ACAM2000 Dose 2</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 2.0x10-7th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O3">
            <title>ACAM2000 Dose 3</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10-7th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O4">
            <title>ACAM2000 Dose 4</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10-6th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Dryvax® Vaccine</title>
            <description>Participants received a single dose of Dryvax® smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Selected Hematology Parameters (Hematocrit, Lymphocyte, and Eosinophil) at Baseline and Day 15 Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</title>
          <population>The hematology parameters were assessed in the intent-to-treat safety population.</population>
          <units>Percentage (%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7" spread="3.58"/>
                    <measurement group_id="O2" value="42.4" spread="3.87"/>
                    <measurement group_id="O3" value="42.2" spread="3.66"/>
                    <measurement group_id="O4" value="42.8" spread="3.69"/>
                    <measurement group_id="O5" value="43.3" spread="3.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit (Day15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2" spread="3.53"/>
                    <measurement group_id="O2" value="41.6" spread="3.86"/>
                    <measurement group_id="O3" value="41.5" spread="3.68"/>
                    <measurement group_id="O4" value="42.1" spread="3.30"/>
                    <measurement group_id="O5" value="42.8" spread="3.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" spread="7.27"/>
                    <measurement group_id="O2" value="30.8" spread="6.68"/>
                    <measurement group_id="O3" value="30.6" spread="7.87"/>
                    <measurement group_id="O4" value="30.4" spread="6.98"/>
                    <measurement group_id="O5" value="30.9" spread="6.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (Day15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" spread="6.88"/>
                    <measurement group_id="O2" value="30.8" spread="7.19"/>
                    <measurement group_id="O3" value="31.3" spread="8.26"/>
                    <measurement group_id="O4" value="31.2" spread="7.36"/>
                    <measurement group_id="O5" value="33.4" spread="7.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="1.89"/>
                    <measurement group_id="O2" value="2.5" spread="2.09"/>
                    <measurement group_id="O3" value="2.5" spread="1.50"/>
                    <measurement group_id="O4" value="2.3" spread="1.37"/>
                    <measurement group_id="O5" value="2.8" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils (Day15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="1.43"/>
                    <measurement group_id="O2" value="2.5" spread="2.02"/>
                    <measurement group_id="O3" value="2.6" spread="1.66"/>
                    <measurement group_id="O4" value="2.5" spread="1.55"/>
                    <measurement group_id="O5" value="3.1" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Selected Hematology Parameters (Red Bood Cell and Platelets) at Baseline and Day 15 Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</title>
        <time_frame>Days 0 (Baseline) and 15 post-vaccination</time_frame>
        <population>The hematology parameters were assessed in the intent-to-treat safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>ACAM2000 Dose 1</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O2">
            <title>ACAM2000 Dose 2</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 2.0x10-7th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O3">
            <title>ACAM2000 Dose 3</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10-7th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O4">
            <title>ACAM2000 Dose 4</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10-6th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Dryvax® Vaccine</title>
            <description>Participants received a single dose of Dryvax® smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Selected Hematology Parameters (Red Bood Cell and Platelets) at Baseline and Day 15 Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</title>
          <population>The hematology parameters were assessed in the intent-to-treat safety population.</population>
          <units>x10^6th/µL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Red Blood Cell count (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="0.35"/>
                    <measurement group_id="O2" value="4.8" spread="0.47"/>
                    <measurement group_id="O3" value="4.8" spread="0.46"/>
                    <measurement group_id="O4" value="4.9" spread="0.40"/>
                    <measurement group_id="O5" value="4.9" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red Blood Cell count (Day15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="0.36"/>
                    <measurement group_id="O2" value="4.7" spread="0.50"/>
                    <measurement group_id="O3" value="4.7" spread="0.50"/>
                    <measurement group_id="O4" value="4.8" spread="0.36"/>
                    <measurement group_id="O5" value="4.8" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="279" spread="69.7"/>
                    <measurement group_id="O2" value="276" spread="54.5"/>
                    <measurement group_id="O3" value="277" spread="71.5"/>
                    <measurement group_id="O4" value="285" spread="58.4"/>
                    <measurement group_id="O5" value="280" spread="75.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets (Day15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="286" spread="66.7"/>
                    <measurement group_id="O2" value="281" spread="61.3"/>
                    <measurement group_id="O3" value="276" spread="67.2"/>
                    <measurement group_id="O4" value="284" spread="63.2"/>
                    <measurement group_id="O5" value="284" spread="77.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinical Chemistry Parameters (Creatinine and Glucose) at Baseline and Day 15 Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</title>
        <time_frame>Days 0 (Baseline) and 15 post-vaccination</time_frame>
        <population>Clinical chemistry parameters were assessed in the intent-to-treat safety population</population>
        <group_list>
          <group group_id="O1">
            <title>ACAM2000 Dose 1</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O2">
            <title>ACAM2000 Dose 2</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 2.0x10-7th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O3">
            <title>ACAM2000 Dose 3</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10-7th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O4">
            <title>ACAM2000 Dose 4</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10-6th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Dryvax® Vaccine</title>
            <description>Participants received a single dose of Dryvax® smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Chemistry Parameters (Creatinine and Glucose) at Baseline and Day 15 Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</title>
          <population>Clinical chemistry parameters were assessed in the intent-to-treat safety population</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatinine (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="0.122"/>
                    <measurement group_id="O2" value="0.94" spread="0.167"/>
                    <measurement group_id="O3" value="0.92" spread="0.187"/>
                    <measurement group_id="O4" value="0.94" spread="0.184"/>
                    <measurement group_id="O5" value="0.97" spread="0.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine (Day 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="0.145"/>
                    <measurement group_id="O2" value="0.96" spread="0.181"/>
                    <measurement group_id="O3" value="0.95" spread="0.184"/>
                    <measurement group_id="O4" value="0.96" spread="0.184"/>
                    <measurement group_id="O5" value="0.98" spread="0.138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" spread="11.7"/>
                    <measurement group_id="O2" value="87" spread="8.7"/>
                    <measurement group_id="O3" value="92" spread="15.3"/>
                    <measurement group_id="O4" value="92" spread="13.4"/>
                    <measurement group_id="O5" value="88" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (Day 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" spread="22.6"/>
                    <measurement group_id="O2" value="90" spread="18.9"/>
                    <measurement group_id="O3" value="90" spread="16.3"/>
                    <measurement group_id="O4" value="94" spread="28.4"/>
                    <measurement group_id="O5" value="95" spread="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinical Chemistry Parameters (Aspartate Transaminase and Alanine Transaminase) at Baseline and Day 15 Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</title>
        <time_frame>Days 0 (Baseline) and 15 post-vaccination</time_frame>
        <population>Clinical chemistry parameters were assessed in the intent-to-treat safety population</population>
        <group_list>
          <group group_id="O1">
            <title>ACAM2000 Dose 1</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O2">
            <title>ACAM2000 Dose 2</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 2.0x10-7th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O3">
            <title>ACAM2000 Dose 3</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10-7th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O4">
            <title>ACAM2000 Dose 4</title>
            <description>Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10-6th plaque-forming units/mL on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Dryvax® Vaccine</title>
            <description>Participants received a single dose of Dryvax® smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Chemistry Parameters (Aspartate Transaminase and Alanine Transaminase) at Baseline and Day 15 Post-vaccination With ACAM2000 or Dryvax® Smallpox Vaccine</title>
          <population>Clinical chemistry parameters were assessed in the intent-to-treat safety population</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Aspartate transaminase (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" spread="13.2"/>
                    <measurement group_id="O2" value="24" spread="9.9"/>
                    <measurement group_id="O3" value="23" spread="10.3"/>
                    <measurement group_id="O4" value="22" spread="6.9"/>
                    <measurement group_id="O5" value="22" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate transaminase (Day 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" spread="11.5"/>
                    <measurement group_id="O2" value="23" spread="8.7"/>
                    <measurement group_id="O3" value="24" spread="10.7"/>
                    <measurement group_id="O4" value="21" spread="10.4"/>
                    <measurement group_id="O5" value="21" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine transaminase (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" spread="16.3"/>
                    <measurement group_id="O2" value="39" spread="19.5"/>
                    <measurement group_id="O3" value="37" spread="17.3"/>
                    <measurement group_id="O4" value="37" spread="15.7"/>
                    <measurement group_id="O5" value="36" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine transaminase (Day 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" spread="20.1"/>
                    <measurement group_id="O2" value="38" spread="20.4"/>
                    <measurement group_id="O3" value="37" spread="19.2"/>
                    <measurement group_id="O4" value="37" spread="16.0"/>
                    <measurement group_id="O5" value="34" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from the day of vaccination for up to 6 months post-vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ACAM2000 Dose 1</title>
          <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0</description>
        </group>
        <group group_id="E2">
          <title>ACAM2000 Dose 2</title>
          <description>Participants received a single dose of ACAM2000 smallpox vaccine, 2.0x10-7th plaque-forming units/mL on Day 0</description>
        </group>
        <group group_id="E3">
          <title>ACAM2000 Dose 3</title>
          <description>Participants received a single dose of ACAM2000 smallpox vaccine, 1.0x10-7th plaque-forming units/mL on Day 0</description>
        </group>
        <group group_id="E4">
          <title>ACAM2000 Dose 4</title>
          <description>Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10-6th plaque-forming units/mL on Day 0</description>
        </group>
        <group group_id="E5">
          <title>Dryvax® Vaccine</title>
          <description>Participants received a single dose of Dryvax® smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 6.0">HIV test positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy Not Otherwise Specified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 6.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="98" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="51" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymph Node Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea Not Otherwise Specified</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="77" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="43" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Feeling Hot</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Rigors</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection Site Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache Not Otherwise Specified</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash Not Otherwise Specified</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eddie Darton, Medical Director</name_or_title>
      <organization>Emergent BioSolutions</organization>
      <phone>240-631-3688</phone>
      <email>dartone@ebsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

